These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 36604205)

  • 21. Motives of Dutch men who have sex with men for daily and intermittent HIV pre-exposure prophylaxis usage and preferences for implementation: A qualitative study.
    Bil JP; van der Veldt WM; Prins M; Stolte IG; Davidovich U
    Medicine (Baltimore); 2016 Sep; 95(39):e4910. PubMed ID: 27684827
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Youth-friendly services and a mobile phone application to promote adherence to pre-exposure prophylaxis among adolescent men who have sex with men and transgender women at-risk for HIV in Thailand: a randomized control trial.
    Songtaweesin WN; Kawichai S; Phanuphak N; Cressey TR; Wongharn P; Saisaengjan C; Chinbunchorn T; Janyam S; Linjongrat D; Puthanakit T;
    J Int AIDS Soc; 2020 Sep; 23 Suppl 5(Suppl 5):e25564. PubMed ID: 32869511
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Perceived Added Value of Bimonthly Injectable Pre-Exposure Prophylaxis According to West African Men Who Have Sex with Men: A Focus Group Study.
    Reyniers T; Fiorentino M; Babo SAY; Ouedraogo M; Kanta I; Agbegnigan LE; Rojas D; Anoma C; Dah TTE; Mensah E; Keita BD; Spire B; Vuylsteke B; Laurent C
    AIDS Patient Care STDS; 2023 Oct; 37(10):480-488. PubMed ID: 37862074
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Decentralizing the delivery of HIV pre-exposure prophylaxis (PrEP) through family physicians and sexual health clinic nurses: a dissemination and implementation study protocol.
    Sharma M; Chris A; Chan A; Knox DC; Wilton J; McEwen O; Mishra S; Grace D; Rogers T; Bayoumi AM; Maxwell J; Shahin R; Bogoch I; Gilbert M; Tan DHS
    BMC Health Serv Res; 2018 Jul; 18(1):513. PubMed ID: 29970087
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Models of HIV Pre-Exposure Prophylaxis Care Used in Title X Family Planning Clinics in the Southern U.S.
    Piper KN; Escoffery C; Sales JM; Sheth AN
    J Adolesc Health; 2021 Mar; 68(3):480-487. PubMed ID: 33160826
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Provider Comfort with Prescribing HIV Pre-Exposure Prophylaxis to Adolescents.
    Pina P; Taggart T; Sanchez Acosta M; Eweka I; Muñoz-Laboy M; Albritton T
    AIDS Patient Care STDS; 2021 Oct; 35(10):411-417. PubMed ID: 34623888
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Self-Consent for HIV Prevention Research Involving Sexual and Gender Minority Youth: Reducing Barriers Through Evidence-Based Ethics.
    Fisher CB; Arbeit MR; Dumont MS; Macapagal K; Mustanski B
    J Empir Res Hum Res Ethics; 2016 Feb; 11(1):3-14. PubMed ID: 26956988
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pre-Exposure Prophylaxis for HIV Prevention in Women: Current Status and Future Directions.
    Hodges-Mameletzis I; Fonner VA; Dalal S; Mugo N; Msimanga-Radebe B; Baggaley R
    Drugs; 2019 Aug; 79(12):1263-1276. PubMed ID: 31309457
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Health Care Provider Barriers to HIV Pre-Exposure Prophylaxis in the United States: A Systematic Review.
    Pleuhs B; Quinn KG; Walsh JL; Petroll AE; John SA
    AIDS Patient Care STDS; 2020 Mar; 34(3):111-123. PubMed ID: 32109141
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Insufficient PrEParation: an assessment of primary care prescribing habits and use of pre-exposure prophylaxis in patients at risk of HIV acquisition at a single medical centre.
    Babiarz J; Nix CD; Bowden S; Roberts R
    Sex Transm Infect; 2023 Jun; 99(4):276-278. PubMed ID: 36759178
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Key barriers and enablers associated with uptake and continuation of oral pre-exposure prophylaxis (PrEP) in the public sector in Zimbabwe: Qualitative perspectives of general population clients at high risk for HIV.
    Gombe MM; Cakouros BE; Ncube G; Zwangobani N; Mareke P; Mkwamba A; Prescott MR; Bhatasara T; Murwira M; Mangwiro AZ; Prust ML
    PLoS One; 2020; 15(1):e0227632. PubMed ID: 31931514
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Policymakers' and healthcare providers' perspectives on the introduction of oral pre-exposure prophylaxis for key populations in Ghana.
    Nagai H; Adiibokah E; Tagoe H; Tun W; Pilgrim NA; Ankomah A; Rahman YAA; Addo SA; Atuahene SK; Essandoh E; Maher S; Kowalski M
    BMC Public Health; 2023 Jun; 23(1):1065. PubMed ID: 37277772
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Addressing disparities in Pre-exposure Prophylaxis (PrEP) access: implementing a community-centered mobile PrEP program in South Florida.
    Butts SA; Young B; Blackmon J; Doblecki-Lewis S
    BMC Health Serv Res; 2023 Nov; 23(1):1311. PubMed ID: 38012701
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Zero knowledge and high interest in the use of long-acting injectable pre-exposure prophylaxis (PrEP) among adolescent men who have sex with men and transgender women in two capital cities in Brazil.
    Pedrana L; Magno L; Zucchi EM; da Silva LAV; Ferraz D; Grangeiro A; Castellanos M; Brasil SA; Dourado I
    BMC Public Health; 2022 Sep; 22(1):1728. PubMed ID: 36096758
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A retrospective study of HIV pre-exposure prophylaxis counselling among non-Hispanic Black youth diagnosed with bacterial sexually transmitted infections in the United States, 2014-2019.
    Watson DL; Shaw PA; Petsis DT; Pickel J; Bauermeister JA; Frank I; Wood SM; Gross R
    J Int AIDS Soc; 2022 Feb; 25(2):e25867. PubMed ID: 35192740
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Provider perspectives on PrEP for adolescent girls and young women in Tanzania: The role of provider biases and quality of care.
    Pilgrim N; Jani N; Mathur S; Kahabuka C; Saria V; Makyao N; Apicella L; Pulerwitz J
    PLoS One; 2018; 13(4):e0196280. PubMed ID: 29702659
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Systematic review of the values and preferences regarding the use of injectable pre-exposure prophylaxis to prevent HIV acquisition.
    Lorenzetti L; Dinh N; van der Straten A; Fonner V; Ridgeway K; Rodolph M; Schaefer R; Schmidt HA; Baggaley R
    J Int AIDS Soc; 2023 Jul; 26 Suppl 2(Suppl 2):e26107. PubMed ID: 37439057
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Qualitative investigation of factors impacting pre-exposure prophylaxis initiation and adherence in sexual minority men.
    Alt M; Rotert P; Conover K; Dashwood S; Schramm AT
    Health Expect; 2022 Feb; 25(1):313-321. PubMed ID: 34904322
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Protocol for a multicenter, real-world study of HIV pre-exposure prophylaxis among men who have sex with men in China (CROPrEP).
    Wang H; Zhang Y; Mei Z; Jia Y; Leuba SI; Zhang J; Chu Z; Ding H; Jiang Y; Geng W; Shang H; Xu J
    BMC Infect Dis; 2019 Aug; 19(1):721. PubMed ID: 31416439
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Perceived Barriers to and Facilitators of Long-Acting Injectable HIV PrEP Use Among Black, Hispanic/Latino, and White Gay, Bisexual, and Other Men Who Have Sex With Men.
    Tran NK; Martinez O; Scheim AI; Goldstein ND; Welles SL
    AIDS Educ Prev; 2022 Oct; 34(5):365-378. PubMed ID: 36181495
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.